ECHO for Diabetes and Multiple Chronic Conditions Study
Diabetes mellitus is a chronic condition that affects the body's ability to process sugar effectively, which over time can increase the risk of heart disease, high blood pressure, and kidney damage. Other chronic conditions include high cholesterol, obesity, and depression. Persons with diabetes mellitus and multiple chronic conditions (DMMC) face higher risks of losing physical or mental function, experiencing other chronic conditions, and death. Most of the residents of New Mexico (NM) belong to groups at risk for developing DMMC. Finding quality healthcare is a key factor, as NM also ranks among the largest, poorest, and most rural states. Primary care providers (PCPs) most often treat DMMC patients, but healthcare teams can lack confidence in managing these complex patients and struggle to keep up with recommended guidelines.
This Project ECHO model (ECHO) for DMMC, a telehealth intervention for healthcare teams, can lead to lower blood sugar levels in DMMC patients being treated at NM primary care clinics. ECHO is a "telementoring" program that trains healthcare teams to provide specialized medical care at their local clinics. This is done by connecting healthcare teams with specialist mentors at academic medical centers through videoconferencing sessions. During ECHO program sessions, groups of healthcare teams hear lectures on key topics in DMMC care from experts, and then give presentations of anonymous patient cases by a healthcare teams for discussion and to receive recommendations.
This clinical pragmatic trial aims to learn if the intervention will improve patient blood sugar levels in persons with DMMC who are being treated at selected health clinic sites throughout New Mexico.
The study aims to answer:
* Whether a 0.5% drop in HbA1c on average can be achieved in the group whose healthcare teams are receiving the ECHO intervention compared to the comparator group, whose providers will not receive the intervention.
* Whether the rate of an individual's HbA1c was greater than 8.5% at the baseline will be reduced by 15% at the end of the intervention.
Researchers will compare health data for patients empaneled to healthcare teams in the study and the usual care comparator group both before and after the intervention period to see whether the ECHO model has a positive influence on test results.
Conditions:
🦠 Diabetes Mellitus
🦠 Chronic Disease
🗓️ Study Start (Actual)
1 October 2024
🗓️ Primary Completion (Estimated)
30 September 2026
✅ Study Completion (Estimated)
30 June 2028
👥 Enrollment (Estimated)
20
🔬 Study Type
INTERVENTIONAL
📊 Phase
NA
Locations:
📍
Santa Fe, New Mexico, United States
Description
Inclusion Criteria:
- * Twenty PMS sites with the highest patient volume.
- * All members of the PMS sites (participants) healthcare teams between 18 and 89 years of age, all genders, and all ethnicities.
Exclusion Criteria:
- * There is no exclusion criteria.
Ages Eligible for Study:
18 Years to 89 Years (ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
No
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported
results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before
being posted on the public website.
Study Registration Dates
- First Submitted
20 May 2024
- First Submitted that Met QC Criteria
3 June 2024
- First Posted
11 June 2024
Study Record Updates
- Last Update Submitted that Met QC Criteria
3 June 2024
- Last Update Posted
11 June 2024
- Last Verified
June 2024